For information on a research trial, contact the Research Office at
469.814.4720 or THHBPResearchDepartment@bswhealth.org.
Principal Investigator: David L. Brown, MD
Assessment of Fractional Flow Reserve Computed tomography versus Single Photo Emission Computed tomography in the diagnosis of hemodynamically significant coronary artery disease.
Principal Investigator: Molly Szerlip, MD
Assess the safety of three-month DAPT in subjects at high risk for bleeding undergoing PCI with the SYNERGY™ Stent System.
Principal Investigator: Sahil Bakshi, DO
Prospective observational drug registry developed to characterize the safety profile (including primarily potential serious hepatic risk) and to describe clinical characteristics and outcomes of patients with pulmonary hypertension who are newly treated with Opsumit in the post-market setting.
Principal Investigator: Steven Kindsvater, MD
The primary objective of this study is to assess the effect of in-hospital initiation of sacubitril/valsartan tablets vs enalapril on the time-averaged proportional change of NT-proBNP from baseline in patients who have been stabilized following hospitalization for acute decompensated heart failure and reduced ejection fraction.
Principal Investigator: Srini P. Potluri, MD
A post-market registry to continue market surveillance of the second generation CorPath® GRX System by Corindus Vascular Robotics. The CorPath GRX System offers improvements in procedural control, enhanced workflow and radiation protection for physicians, patients and staff.
Principal Investigator: Adam Shapira, MD
Assess the safety of the 1457Q Quartet™ Quadripolar LV lead at three months in a patient population indicated for cardiac resynchronization.
The "Radiance-HTN" Study — A Study of the ReCor Medical Paradise System in Clinical Hypertension — Demonstrate the ability of the Paradise® Renal Denervation System to effectively reduce systolic daytime ambulatory BP (ABP) in hypertensive subjects.
To evaluate the safety and effectiveness of the Ranger™ Paclitaxel Coated Balloon for treating lesions located in the superficial femoral and proximal popliteal arteries.
Principal Investigator: Elizabeth Holper, MD
The primary objective of this clinical trial is to evaluate whether the RenalGuard® Therapy is superior to a well-studies standard hydration protocol for preventing the incidence of contrast induce nephropathy after a catheterization procedure which uses iodinated contrast media.
Resolute Integrity™ US Extended Length Sub-Study (RI-US XL) — Conduct a prospective, multi-center evaluation of the procedural and clinical outcomes of subjects that are treated with the commercially available 34 MM and 38 MM Medtronic Resolute Integrity ZOTAROLIMUS-ELUTING coronary stem system.
National Biological Sample and Data Repository for Pulmonary Arterial Hypertension - Establish a national biorepository of biological samples and genetic data of patients with WHO Group 1 PAH.
Physicians are members of the medical staff at one of Baylor Health Care System's subsidiary, community or affiliated medical centers and are neither employees nor agents of those medical centers, The Heart Hospital Baylor Plano or Baylor Health Care System.